These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 30698208

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms.
    Mundt-Petersen U, Odin P.
    Int Rev Neurobiol; 2017; 134():1019-1044. PubMed ID: 28805563
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 5. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
    Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA.
    J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
    [Abstract] [Full Text] [Related]

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.
    Richter D, Bartig D, Jost W, Jörges C, Stumpe B, Gold R, Krogias C, Tönges L.
    J Neural Transm (Vienna); 2019 Jul; 126(7):879-888. PubMed ID: 31222604
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Apomorphine in advanced Parkinson disease].
    Bogucki A.
    Neurol Neurochir Pol; 2013 May; 47(5):476-83. PubMed ID: 24166569
    [Abstract] [Full Text] [Related]

  • 16. [Proposed alternative to standard apomorphine challenge test].
    Martínez-Castrillo JC, Burguera JA.
    Rev Neurol; 2012 May; 55 Suppl 1():S11-3. PubMed ID: 23169227
    [Abstract] [Full Text] [Related]

  • 17. Carbidopa levodopa enteral suspension.
    Seeberger LC, Hauser RA.
    Expert Opin Pharmacother; 2015 May; 16(18):2807-17. PubMed ID: 26595228
    [Abstract] [Full Text] [Related]

  • 18. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
    van Laar T, Borgemeester R.
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S22-S27. PubMed ID: 27998652
    [Abstract] [Full Text] [Related]

  • 19. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T.
    Neurodegener Dis Manag; 2014 Dec; 4(3):271-82. PubMed ID: 25095821
    [Abstract] [Full Text] [Related]

  • 20. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.